MX2019014375A - Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. - Google Patents

Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.

Info

Publication number
MX2019014375A
MX2019014375A MX2019014375A MX2019014375A MX2019014375A MX 2019014375 A MX2019014375 A MX 2019014375A MX 2019014375 A MX2019014375 A MX 2019014375A MX 2019014375 A MX2019014375 A MX 2019014375A MX 2019014375 A MX2019014375 A MX 2019014375A
Authority
MX
Mexico
Prior art keywords
antibody
antigen binding
binding fragment
medical use
application
Prior art date
Application number
MX2019014375A
Other languages
English (en)
Inventor
Hu Qiyue
Cao Guoqing
Zhang Lianshan
Jiang Jiahua
Yan Shude
Qian Xueming
Teng Fei
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019014375A publication Critical patent/MX2019014375A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Abstract

Se proporcionan un anticuerpo anti-CD40, un fragmento de union a antigeno del mismo, y un uso medico del mismo; tambien se proporcionan un anticuerpo quimerico y un anticuerpo humanizado que incluye una region de CDR del anticuerpo anti-CD40, una composicion farmaceutica que incluye el anticuerpo anti-CD40 humano y el fragmento de union al antigeno del mismo, y una aplicacion del mismo como un agente anti-cancer; en particular, se proporcionan un anticuerpo anti-CD40 humanizado, y una aplicacion del mismo en la preparacion de un farmaco para tratar une enfermedad o trastorno mediado por CD40.
MX2019014375A 2017-06-01 2018-05-31 Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo. MX2019014375A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710402559 2017-06-01
PCT/CN2018/089252 WO2018219327A1 (zh) 2017-06-01 2018-05-31 抗cd40抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
MX2019014375A true MX2019014375A (es) 2020-01-23

Family

ID=64454385

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014375A MX2019014375A (es) 2017-06-01 2018-05-31 Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.

Country Status (11)

Country Link
US (1) US11525005B2 (es)
EP (1) EP3632932A4 (es)
JP (1) JP7257971B6 (es)
KR (1) KR20200012920A (es)
CN (1) CN110267989B (es)
AU (1) AU2018278051A1 (es)
BR (1) BR112019025048A2 (es)
CA (1) CA3064298A1 (es)
MX (1) MX2019014375A (es)
TW (1) TWI699376B (es)
WO (1) WO2018219327A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020108611A1 (zh) * 2018-11-30 2020-06-04 江苏恒瑞医药股份有限公司 抗cd40抗体、其抗原结合片段及其医药用途
CN112839961B (zh) * 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
WO2020253722A1 (en) * 2019-06-17 2020-12-24 Eucure (Beijing) Biopharma Co., Ltd Anti-cd40 antibodies and uses thereof
TW202144421A (zh) * 2020-03-30 2021-12-01 大陸商正大天晴藥業集團股份有限公司 結合cd40的抗體及其用途
CN115403670A (zh) * 2021-05-26 2022-11-29 安徽瀚海博兴生物技术有限公司 抗cd40抗体及其用途
CN117940456A (zh) * 2021-09-24 2024-04-26 正大天晴药业集团股份有限公司 抗cd40抗体及其用途
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
TW202340256A (zh) * 2022-04-02 2023-10-16 大陸商和鉑醫藥（上海）有限責任公司 一種標靶ｃｄ４０的抗原結合蛋白及其製備和應用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2002211366A1 (en) 2000-10-02 2002-04-15 Chiron Corporation Human anti-cd40 antibodies
EP2009027B1 (en) * 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
SI1682180T1 (sl) * 2003-11-04 2010-03-31 Novartis Vaccines & Diagnostic Antagonist anti cd monoklonskih antiteles in postopek za njihovo uporabo
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
BRPI0510317A (pt) 2004-04-27 2007-10-16 Novartis Vaccines & Diagnostic anticorpos monoclonais anti-cd40 antagonistas e métodos para seu uso
JP4780589B2 (ja) * 2004-07-08 2011-09-28 内山工業株式会社 フッ素ゴム組成物
KR100991010B1 (ko) 2005-05-26 2010-10-29 제넨테크, 인크. 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
CN102448989B (zh) * 2009-03-10 2015-09-30 贝勒研究院 抗-cd40抗体及其用途
EA031872B1 (ru) 2010-03-31 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Гуманизированное антитело к cd40, его применение, фармацевтическая композиция, содержащая это антитело, и выделенный полинуклеотид, кодирующий его
CN105859889B (zh) * 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
TW201245225A (en) * 2011-04-21 2012-11-16 Bristol Myers Squibb Co Antibody polypeptides that antagonize CD40
CN106928362B (zh) * 2011-04-29 2021-10-26 埃派斯进有限公司 抗-cd40抗体及其使用方法
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
US9676861B2 (en) 2012-10-30 2017-06-13 Apexigen, Inc. Anti-CD40 antibodies and methods of use
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
DK3283527T3 (da) 2015-04-13 2021-03-08 Five Prime Therapeutics Inc Kombinationsterapi mod cancer
US10174121B2 (en) 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
CA2990012A1 (en) 2015-06-29 2017-01-05 Bristol-Myers Squibb Company Antibodies to cd40
CA3002789A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用

Also Published As

Publication number Publication date
TW201902925A (zh) 2019-01-16
RU2019141751A3 (es) 2021-08-26
CN110267989A (zh) 2019-09-20
AU2018278051A1 (en) 2020-01-30
JP7257971B2 (ja) 2023-04-14
KR20200012920A (ko) 2020-02-05
EP3632932A4 (en) 2021-08-18
JP2020521504A (ja) 2020-07-27
BR112019025048A2 (pt) 2020-06-30
RU2019141751A (ru) 2021-07-12
CA3064298A1 (en) 2018-12-06
US20200148778A1 (en) 2020-05-14
EP3632932A1 (en) 2020-04-08
US11525005B2 (en) 2022-12-13
WO2018219327A1 (zh) 2018-12-06
JP7257971B6 (ja) 2023-07-24
TWI699376B (zh) 2020-07-21
CN110267989B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
MX2019014375A (es) Anticuerpo anti-cd40, fragmento de union a antigeno del mismo, y uso medico del mismo.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
PH12016501120A1 (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
MX2020008977A (es) Formulaciones de anticuerpos de her2 subcutaneas.
MX2017012965A (es) Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo.
BR112018009064A2 (pt) anticorpo de pd-l1, fragmento de ligação ao antígeno do mesmo e aplicação médica do mesmo
MY191423A (en) Binding molecules specific for cd73 and uses thereof
MX2018014175A (es) Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
ZA202004701B (en) Anti-b7-h4 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
NZ743316A (en) Anti-dr5 antibodies and methods of use thereof
NZ726513A (en) Anti-gitr antibodies and methods of use thereof
MX2017016253A (es) Anticuerpos para cd40.
MX2020012567A (es) Anticuerpos anti-ox40 y metodos de uso.
MX2018010672A (es) Anticuerpos para cumulo de diferenciación 40 (cd40) con actividad agonista mejorada.
MX2020007406A (es) Anticuerpo pd-l1, fragmento de union al antigeno del mismo y uso farmaceutico del mismo.
MX2021001143A (es) Anticuerpo de union a il-4r humana, fragmento de union a antigeno y uso medico del mismo.
PH12020551447A1 (en) Antibodies
MX2020010119A (es) Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo.
MX2018009264A (es) Anticuerpo de trombina, fragmento de antigeno y sus usos farmaceuticos.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2019003779A (es) Uso médico de un conjugado anticuerpo anti-c-met-fármaco citotóxico.
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.